Jeevan Scientific Technology Receives 'Hold' Rating, But Faces Challenges in Long-Term Growth

Jeevan Scientific Technology, a microcap pharmaceutical and drug company, has recently received a 'Hold' rating from MarketsMOJO on January 15, 2024. This upgrade is based on the company's strong ability to service its debt, with a low Debt to EBITDA ratio of 0.86 times.
The stock is currently in a bullish range, with technical indicators such as MACD, Bollinger Band, and KST showing positive trends. However, the majority of shareholders are non-institutional, which may indicate a lack of confidence from larger investors.

Despite these positive factors, Jeevan Scientific Technology has shown poor long-term growth, with an annual rate of -213.67% in operating profit over the last 5 years. In addition, the company's results for September 2023 were flat, indicating a lack of significant progress.

Investing in this stock may also carry some risk, as the company has negative operating profits and is trading at a higher risk compared to its historical valuations. In the past year, while the stock has generated a return of 6.90%, its profits have fallen by -157.1%.

Furthermore, Jeevan Scientific Technology has underperformed the market in the last year, with a return of only 6.90% compared to the market's (BSE 500) return of 28.66%. This may be a cause for concern for potential investors.

In conclusion, while Jeevan Scientific Technology has some positive aspects, such as its ability to service debt and current bullish trend, it also has some red flags, such as poor long-term growth and underperformance in the market. Investors should carefully consider these factors before making any decisions regarding this microcap stock.